Renal cell carcinoma · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-HLRCC-SUSPICION-PREVENTION-GENETIC-COUNSELING`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-RCC`
Sources	`SRC-ESMO-RCC-2024` `SRC-NCCN-KIDNEY-2025`

Notes

STUB — v0.2-B hereditary pilot (HLRCC). HLRCC Family Alliance International Surveillance Guidelines + NCCN Genetic/Familial High-Risk Kidney as new SRC entities are v0.2-B authoring backlog. Two-Co-Lead signoff queued.

Used By

Indication

IND-HLRCC-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCE - IND-HLRCC-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCE

Red flag

RF-HLRCC-FAMILY-HISTORY-SUSPICION - Family pedigree suggestive of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) syn...